| Mar-2025 | Dec-2024 | Sep-2024 | Jun-2024 | Mar-2024 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 1.84% | 1.84% | 1.84% | 2.02% | 2.02% |
Indian | 52.05% | 52.06% | 52.07% | 52.57% | 52.57% |
Total Promoter | - | - | - | - | - |
Institutions | 39.98% | 39.98% | 39.71% | 38.13% | 35.84% |
Non-Institutions | 5.83% | 5.82% | 6.03% | 6.96% | 9.23% |
Total Non-Promoter | 45.82% | 45.8% | 45.75% | 45.09% | 45.08% |
Custodian | 0.26% | 0.28% | 0.33% | 0.3% | 0.31% |
Total | 100% | 100% | 100% | 100% | 100% |
Dr Lal PathLabs declared a fourth interim dividend of ₹6 per share for 2025, reflecting its strong cash generation and shareholder remittance focus.
The company declared a third interim dividend of ₹6 per share (60% on a face value of ₹10) for FY25.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
